© 2021 MJH Life Sciences and Practical Cardiology. All rights reserved.
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
November 15, 2020
Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.
October 28, 2020
An analysis of the Dallas Heart Study from UTSW details how use of CAC scoring can help determine what patients would stand to benefit from aspirin use for primary prevention.
August 21, 2020
An analysis of data from a Society of Vascular Surgeons registry is shedding light on the use of DAPT in patients following peripheral vascular interventions.
August 13, 2020
A meta-analysis of 4 randomized trials is shedding light on the efficacy and safety of direct oral anticoagulant use for reducing recurrent VTE in patients with cancer.
August 03, 2020
A new network meta-analysis offers an overview of the clinical benefit of less than 6 months, 6-month, 12-month, and extended periods of DAPT therapy after PCI with drug-eluting stents.
July 27, 2020
S. Claiborne Johnston discusses the results of the phase 3 THALES trial examining use of ticagrelor dual antiplatelet therapy for reducing subsequent stroke in patients with AIS or TIA.
July 21, 2020
A prespecified analysis of ISAR-REACT 5 is shedding light on the effectiveness and safety of age- and weight-adjusted prasugrel versus ticagrelor following ACS.
July 19, 2020
Results of the phase 3 THALES trial detail the effect of ticagrelor DAPT for reducing the risk of stroke and death in patients with acute ischemic stroke or transient ischemic attack.
July 17, 2020
New data suggests heparin could mitigate SARS-CoV-2 ability to bind to human cells.
July 15, 2020
An observational study in Sweden is challenging current guidelines in regard to preference of ticagrelor over clopidogrel for patients with ACS undergoing PCI.